Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECTION extension study of daclizumab HYP monotherapy in relapsing-remitting multiple sclerosis
2009-015318-23Phase 2Completed
- Sponsor
- Biogen
- Start
- Dec 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daclizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Primary endpoint: Adverse events. Started Dec 2009; status: completed.
02
Drugs
daclizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2009-015318-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015318-23.